Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Systemic Therapy Selection for Advanced EOC

July 30th 2019

TRK Inhibition: Future Challenges and Evolutions

July 30th 2019

Use of TRK Inhibition in Specific Tumor Types

July 30th 2019

The Importance and Evolution of NGS Testing

July 30th 2019

Envisioning Use of TRK Inhibitors in Clinical Practice

July 30th 2019

Other Approaches to TRK-Fusion Cancers

July 30th 2019

TRK Inhibition in CNS Tumors or Metastases

July 30th 2019

Treating Pediatric Patients With TRK Inhibitors

July 30th 2019

Considering Available Data for Entrectinib

July 30th 2019

TRK Inhibition: Personal Experience With Larotrectinib

July 30th 2019

Larotrectinib for NTRK Fusions: Patient Selection

July 30th 2019

Updated Data for Larotrectinib

July 30th 2019

Larotrectinib: The First FDA-Approved TRK Inhibitor

July 30th 2019

NTRK: An Attractive Target for Therapy

July 30th 2019

Larotrectinib Likely to Get EU Nod for NTRK+ Tumors

July 26th 2019

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of larotrectinib for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.

Turning to Broad Sequencing Panels for Targeted Therapy in Advanced NSCLC

July 26th 2019

Mohammad Razaq, MD, discusses how the detection of driver mutations has changed the way treatment is approached in advanced non–small cell lung cancer.

The Future Treatment Landscape of AML

July 22nd 2019

Targeting IDH1/2 in AML

July 22nd 2019

Relapsed vs. Refractory Data for FLT3 Inhibitors in AML

July 22nd 2019

Data Supporting Quizartinib in FLT3+ R/R AML

July 22nd 2019